Dr. Gunderson is passionate about medical oncology and the treatment of all forms of cancer, with a special interest in breast cancer. She partners with her patients to determine the best treatment options for their cancer. Dr. Gunderson believes in providing compassionate care, and treats her patients as she would want a loved one to be treated.
In her free time, Dr. Gunderson enjoys cooking, gardening and spending time with her family.
CAMBRIA-2: A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.
View DetailsA Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer.
View DetailsA Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy.
View Details